Indication intelligence, analysis and sector perception

Solid Biosciences (SLDB) clinical hold removed on SGT-001 DMD (Duchenne muscular dystrophy) treatment

June 18, 2018 9:34am

SLDB closed up +$1.81 on Friday and is up +$2.70 or +10.19% in the pre-market

The clinical hold was imposed in March and came after the unexpected hospitalization of a patient in the P1/2 trial, called Ignite DMD.

Solid Biosciences Inc. shares surged 10+% in premarket trade Monday, the U.S. FDA has lifted its clinical hold on SGT-001, SLDB's treatment for Duchenne muscular dystrophy, allowing a P1/11 trial to resume. SGT-001 is a gene therapy that aims to improve protein expression for patients with DMD, a rare degenerative disease.

The clinical hold was imposed in March and came after the unexpected hospitalization of a patient in the phase 1/2 trial, called Ignite DMD.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

7 hours 54 min ago
RegMed Investors’ (RMi) pre-open: the down draft doesn’t seem to be over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.